Meiji Seika Pharma initiates ME3241 Phase I study, inverting checkpoint blockade logic for autoimmune therapy
Meiji Seika Pharma initiates Phase I of ME3241, a PD-1 agonist antibody for autoimmune disease in Australia. Read the clinical analysis.
FDA IND clearance propels ViroMissile’s IDOV-Immune into major U.S. cancer centers
ViroMissile expands its IDOV-Immune Phase I trial to U.S. sites after FDA IND clearance. Discover what this means for systemic oncolytic therapy.